Star- and Banana-Shaped Oligomers with a Pyrimidine Core
[MH]+, 270 (13) [MH]+, 272 (64) [MH]+. C12H11Cl2N3 (268.14):
calcd. C 53.75, H 4.13, N 15.67; found C 53.72, H 4.13, N 15.63.
2-(4-Methylsulfanylphenyl)-4,6-di(2-thienyl)pyrimidine (11): Suzuki
cross-coupling reaction of 10 (100 mg, 0.36 mmol) with (4-methyl-
sulfanylphenyl)boronic acid (1.1 g, 8.1 mmol) according to the ge-
neral procedure (t = 40 h) gave after purification by recrystalli-
sation in heptane 120 mg (91%) of 11 as a yellow solid; m.p.
192 °C. 1H NMR (300 MHz, CDCl3): δ = 2.59 (s, 3 H, SCH3), 7.22
(dd, J1 = 4.9, J2 = 3.8 Hz, 2 H, 4’-H), 7.39 (d, J = 8.8 Hz, 2 H,
Ph-H), 7.58 (dd, J1 = 4.9, J2 = 1.0 Hz, 2 H, 5’-H), 7.69 (s, 1 H, 5-
H), 7.91 (dd, J1 = 3.8, J2 = 1.0 Hz, 2 H, 3’-H) 8.56 (d, J = 8.8 Hz,
2 H, Ph-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 15.7, 106.7,
126.0, 126.3, 127.5, 128.7, 129.1, 130.2, 134.4, 142.5, 143.6,
4-[4-(Dimethylamino)phenyl]-2,6-bis(4-methoxyphenyl)pyrimidine
(6): Suzuki cross-coupling reaction of 5 (100 mg, 0.37 mmol) with
(4-methoxyphenyl)boronic acid (281 mg, 1.85 mmol) according to
the general procedure (t = 40 h) gave after purification by column
chromatography [silica gel, eluent petroleum ether/ethyl acetate
(8:2)] 120 mg (75%) of 6 as an orange solid; m.p. 157 °C. 1H NMR
(300 MHz, CDCl3): δ = 3.00 [s, 6 H, N(CH3)2], 3.84 (s, 3 H, OCH3),
3.87 (s, 3 H, OCH3), 6.76 (d, J = 9 Hz, 2 H, Ph-H), 7.04–7.00 (m,
4 H, Ph-H), 7.74 (s, 1 H, 5-H), 8.22–8.16 (m, 4 H, Ph-H), 8.67 (d,
J = 9.0 Hz, 2 H, Ph-H) ppm. 13C NMR (75 MHz, CDCl3): δ =
40.4, 40.6, 55.8, 108.3, 114.0, 114.6, 125.3, 128.1, 129.0, 129.1,
159.8 ppm. IR: ν = 1575, 1557, 1524, 1365, 822, 716, 702 cm–1.
˜
C19H14N2S3 (366.52): calcd. C 62.26, H 3.85, N 7.64, S 26.25;
found C 62.60, H 3.61, N 7.41, S 25.93.
130.4, 131.0, 132.0, 152.5, 163.7, 164.1, 164.5 ppm. IR: ν = 1609,
˜
1568, 1510, 1363, 1245, 1170 cm–1. C26H25N3O2 (411.19): calcd. C
75.89, H 6.12, N 10.21; found C 75.85, H 6.09, N 10.15.
2,4,6-Tris[4Ј-(decyloxy)biphenyl-4-yl]pyrimidine (12): Suzuki cross-
coupling reaction of 2,4,6-trichloropyrimidine (103 mg, 0.55 mmol)
with [4Ј-(decyloxy)biphenyl-4-yl]boronic acid (990 mg, 2.79 mmol)
according to the general procedure (t = 40 h) gave after purification
by column chromatography [silica gel, eluent heptane/ethyl acetate
(9:1)] and by recrystallisation in methylcyclohexane 293 mg (53%)
of 12 as a pale-yellow solid; m.p. 191 °C. 1H NMR (300 MHz,
CDCl3): δ = 0.87 (t, J = 6.0 Hz, 9 H, 3ϫCH3), 1.42–1.22 (m, 42 H,
21ϫCH2), 1.79–1.74 (m, 6 H, 3ϫOCH2CH2), 3.92 (t, J = 6.6 Hz, 6
H, 3ϫOCH2), 7.07 (d, J = 8.8 Hz, 6 H, Ph-H), 7.68 (d, J = 8.8 Hz,
6 H, Ph-H), 7.78 (d, J = 8.8 Hz, 6 H, Ph-H), 8.06 (s, 1 H, 5-H),
8.35 (d, J = 8.8 Hz, 4 H, Ph-H), 8.82 (d, J = 8.8 Hz, 2 H, Ph-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 14.5, 23.1, 26.5, 29.7,
29.8 (2 C), 29.9, 30.0, 32.2, 68.5, 110.0, 115.2, 127.0, 127.4, 128.1,
128.6, 129.3, 132.9, 133.4, 136.1, 136.9, 143.2, 143.5, 159.6,
2,4,6-Tris[4-(dimethylamino)phenyl]pyrimidine (7): Suzuki cross-
coupling reaction of 5 (100 mg, 0.37 mmol) with [4-(dimeth-
ylamino)phenyl]boronic acid (305 mg, 1.85 mmol) according to the
general procedure (t = 40 h) gave after purification by column
chromatography [silica gel, eluent petroleum ether/ethyl acetate
1
(8:2)] 108 mg (67%) of 7 as a red solid; m.p. Ͼ250 °C. H NMR
(300 MHz, CDCl3): δ = 3.06 [s, 18 H, N(CH3)2], 6.85–6.81 (m, 6
H, Ph-H), 7.73 (s, 1 H, 5-H), 8.22 (d, J = 9.1 Hz, 4 H, Ph-H), 8.63
(d, J = 9.0 Hz, 2 H, Ph-H) ppm. 13C NMR (75 MHz, CDCl3): δ =
40.7, 40.8, 106.2, 112.0, 112.3, 126.2, 127.5, 128.8, 130.0, 152.3,
163.9, 165.0 ppm. IR: ν = 1610, 1570, 1523, 1361, 1193, 1169,
˜
810 cm–1. C28H31N5 (437.26): calcd. C 76.85, H 7.14, N 16.00;
found C 76.55, H 6.98, N 16.09.
164.7 ppm. IR: ν = 2923, 2852, 1604, 1574, 1497, 1248, 1192,
˜
821 cm–1. C70H88N2O3 (1004.68): calcd. C 83.62, H 8.82, N 2.79;
found C 83.61, H 8.79, N 2.81.
2-Chloro-4,6-di(furan-2-y)pyrimidine (8) and 2,4,6-Tri(furan-2-yl)-
pyrimidine (9): Suzuki cross-coupling reaction of 2,4,6-trichloropyr-
imidine (634 mg, 3.46 mmol) with (furan-2-yl)boronic acid (1.93 g,
17.3 mmol) according to the general procedure (t = 40 h) gave after
purification by column chromatography [silica gel, eluent heptane/
ethyl acetate (9:1)] 348 mg (41%) of 8 and 410 mg (43%) of 9 both
2,4,6-Tris[4Ј-(dimethylamino)biphenyl-4-yl]pyrimidine (13): Suzuki
cross-coupling reaction of 2,4,6-trichloropyrimidine (143 mg,
0.78 mmol) with (4Ј-decyloxybiphenyl-4-yl)boronic acid (937 mg,
3.0 mmol) according to the general procedure A (t = 40 h) gave
after purification by recrystallisation in methylcyclohexane 195 mg
1
as colourless solids. 8: M.p. 188 °C (ref.[23] 187–188 °C). H NMR
(300 MHz, CDCl3): δ = 6.64 (dd, J1 = 1.7, J2 = 3.6 Hz, 2 H, 4’-H),
7.41 (d, J2 = 3.6 Hz, 2 H, 5Ј-H), 7.67 (d, J1 = 1.7 Hz, 2 H, 3’-H),
7.85 (s, 1 H, 5-H) ppm. 13C (75 MHz, CDCl3): δ = 106.8, 113.3,
1
(39%) of 13 as a yellow solid; m.p. Ͼ250 °C. H NMR (300 MHz,
CDCl3): δ = 3.05 (s, 18 H, NCH3), 6.87 (d, J = 8.8 Hz, 6 H, Ph-
H), 7.65 (d, J = 8.8 Hz, 6 H, Ph-H), 7.78 (d, J = 8.8 Hz, 6 H, Ph-
H), 8.06 (s, 1 H, 5-H), 8.38 (d, J = 8.8 Hz, 4 H, Ph-H), 8.80 (d, J
= 8.8 Hz, 2 H, Ph-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 40.9,
41.0, 109.7, 113.1, 126.5, 126.8, 128.0, 128.2, 128.5, 129.0, 129.3,
114.5, 146.3, 151.1, 158.5, 161.9 ppm. IR: ν = 1608, 1548, 1482,
˜
1265, 756 cm–1. C12H7ClN2O2 (246.02): calcd. C 58.43, H 2.86, N
1
11.36; found C 58.35, H 2.69, N 11.20. 9: M.p. 168 °C. H NMR
(300 MHz, CDCl3): δ = 6.64 (m, 3 H, 4Ј- and 4ЈЈ-H), 7.41 (d, J2 =
3.4 Hz, 2 H, 5’-H), 7.43 (d, J2 = 3.4 Hz, 1 H, 5’’-H), 7.66 (d, J1 =
1.7 Hz, 2 H, 3’-H), 7.68 (d, J1 = 1.7 Hz, 1 H, 3’’-H), 7.78 (s, 1 H,
5-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 106.2, 112.4, 112.9,
135.6, 136.5, 143.5, 143.8, 150.6, 150.7, 164.7, 164.8 ppm. IR: ν =
˜
1603, 1501, 1361, 1200, 1166, 811, 787 cm–1. C46H43N5 (665.35):
calcd. C 82.97, H 6.51, N 10.52; found C 83.02, H 6.40, N 10.64.
113.0, 114.1, 145.4, 145.5, 152.3, 152.6, 156.6, 158.2 ppm. IR: ν =
˜
2,4,6-Tris{4-[4-(decyloxyphenyl)ethynyl]phenyl}pyrimidine (15): Su-
zuki cross-coupling reaction of 2,4,6-trichloropyrimidine (166 mg,
0.91 mmol) with 14[24] (1.72 g, 4.55 mmol) according to the general
1608, 1535, 1486, 1006, 760, 739 cm–1. C16H10N2O3 (278.0): calcd.
C 69.06, H 3.62, N 10.07; found C 68.96, H 3.75, N 9.95.
2-Chloro-4,6-di(2-thienyl)pyrimidine (10): Suzuki cross-coupling re-
action of 2,4,6-trichloropyrimidine (300 mg, 1.63 mmol) with 2-thi-
enylboronic acid (1.1 g, 8.1 mmol) according to the general pro-
cedure (t = 40 h) gave after purification by column chromatography
[silica gel, eluent heptane/ethyl acetate (9:1)] 155 mg (34%) of 10
as a yellow solid; m.p. 191 °C (ref.[23] 195–196°°C). 1H NMR
(300 MHz, CDCl3): δ = 7.20 (dd, J1 = 4.9, J2 = 3.8 Hz, 2 H, 4’-H),
procedure A (t = 40 h) gave after purification by column
chromatography [silica gel, eluent heptane/ethyl acetate (9:1)],
recrystallisation in a mixture of methylcyclohexane and ethyl ace-
tate and washings with toluene 157 mg (16%) of 15 as an orange
solid; m.p. 64 °C. 1H NMR (300 MHz, CDCl3): δ = 0.87 (t, J =
6.0 Hz, 9 H, 3ϫCH3), 1.42–1.22 (m, 42 H, 21ϫCH2),1.79–1.74
(m, 6 H, 3ϫOCH2CH2), 3.97 (t, J = 6.6 Hz, 6 H, OCH2), 6.90 (d,
7.59 (dd, J1 = 4.9, J2 = 1.0 Hz, 2 H, 5’-H), 7.67 (s, 1 H, 5-H), 7.87 J = 8.9 Hz, 6 H, Ph-H), 7.53–7.51 (d, J = 8.9 Hz, 6 H, Ph-H), 7.69
(dd, J1 = 3.8, J2 = 1.0 Hz, 2 H, 3’-H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 106.3, 127.5, 127.6, 130.1, 139.6, 160.4, 160.8 ppm.
(d, J = 8.9 Hz, 6 H, Ph-H), 8.01 (s, 1 H, 5-H), 8.27 (d, J = 8.9 Hz,
4 H, Ph-H), 8.69 (d, J = 8.9 Hz, 2 H, Ph-H) ppm. 13C NMR
IR: ν = 1573, 1490, 1434, 1259, 714 cm–1. C H ClN S (277.97): (75 MHz, CDCl3): δ = 14.5, 23.1, 26.4, 29.6, 29.7, 29.8, 29.9, 30.0,
˜
12
7
2 2
calcd. C 51.70, H 2.53, N 10.05, S 23.00; found C 51.61, H 2.60,
N 10.03, S 22.78.
32.3, 68.5, 88.2, 88.7, 91.9, 92.4, 114.9, 115.0, 115.1, 115.3, 126.4,
126.7, 127.5 (2 C), 128.7, 132.3 (2 C), 133.6 (2 C), 138.8, 137.7,
Eur. J. Org. Chem. 2008, 3129–3140
© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
3137